Advertisement
Screener

GENELUX CORPORATION (GNLX) Capital Expenditures

2.8 / 5 stars · 68/120 Roast Me

GENELUX CORPORATION Capital Expenditures

GENELUX CORPORATION (GNLX) reported Capital Expenditures of $2.45 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Cash Flow › Investing Activities

us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-13

  • GENELUX CORPORATION payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $1.53M, a 1232.17% increase year-over-year.
  • GENELUX CORPORATION payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $921.00K, a 2970.00% increase year-over-year.
  • GENELUX CORPORATION payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $436.00K, a 354.17% increase year-over-year.
  • GENELUX CORPORATION payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $517.00K, a 1814.81% increase year-over-year.
  • GENELUX CORPORATION payments to acquire property, plant, and equipment for fiscal 2025 was $1.10M, a 188.19% increase from fiscal 2024.
  • GENELUX CORPORATION payments to acquire property, plant, and equipment for fiscal 2024 was $381.00K, a 62.83% decline from fiscal 2023.
  • GENELUX CORPORATION payments to acquire property, plant, and equipment for fiscal 2023 was $1.02M, a 1991.84% increase from fiscal 2022.
  • GENELUX CORPORATION payments to acquire property, plant, and equipment for fiscal 2022 was $49.00K.
Period endPayments to Acquire Property, Plant, and Equipment 3 monthPayments to Acquire Property, Plant, and Equipment 6 monthPayments to Acquire Property, Plant, and Equipment 9 monthPayments to Acquire Property, Plant, and Equipment 12 month
2026-06-30$1.53M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13
$2.45M
10-Q · filed 2026-08-13
$2.89M
derived: sum of 3 quarters · filed 2026-08-13
$3.41M
derived: sum of 4 quarters · filed 2026-08-13
2026-03-31$921.00K
10-Q · filed 2026-05-07
$1.36M
derived: sum of 2 quarters · filed 2026-05-07
$1.87M
derived: sum of 3 quarters · filed 2026-05-07
$1.99M
derived: sum of 4 quarters · filed 2026-08-13
2025-12-31$436.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19
$953.00K
derived: sum of 2 quarters · filed 2026-03-19
$1.07M
derived: sum of 3 quarters · filed 2026-08-13
$1.10M
10-K · filed 2026-03-19
2025-09-30$517.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
$632.00K
derived: sum of 2 quarters · filed 2026-08-13
$662.00K
10-Q · filed 2025-11-05
$758.00K
derived: sum of 4 quarters · filed 2026-08-13
2025-06-30$115.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13
$145.00K
10-Q · filed 2026-08-13
$241.00K
derived: sum of 3 quarters · filed 2026-08-13
$268.00K
derived: sum of 4 quarters · filed 2026-08-13
2025-03-31$30.00K
10-Q · filed 2026-05-07
$126.00K
derived: sum of 2 quarters · filed 2026-05-07
$153.00K
derived: sum of 3 quarters · filed 2026-05-07
$381.00K
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31$96.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19
$123.00K
derived: sum of 2 quarters · filed 2026-03-19
$351.00K
derived: sum of 3 quarters · filed 2026-03-19
$381.00K
10-K · filed 2026-03-19
2024-09-30$27.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
$255.00K
derived: sum of 2 quarters · filed 2025-11-05
$285.00K
10-Q · filed 2025-11-05
$528.00K
derived: sum of 4 quarters · filed 2025-11-05
2024-06-30$228.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
$258.00K
10-Q · filed 2025-08-07
$501.00K
derived: sum of 3 quarters · filed 2025-08-07
$778.00K
derived: sum of 4 quarters · filed 2025-08-07
2024-03-31$30.00K
10-Q · filed 2025-05-06
$273.00K
derived: sum of 2 quarters · filed 2025-05-06
$550.00K
derived: sum of 3 quarters · filed 2025-05-06
$946.00K
derived: sum of 4 quarters · filed 2025-05-06
2023-12-31$243.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28
$520.00K
derived: sum of 2 quarters · filed 2025-03-28
$916.00K
derived: sum of 3 quarters · filed 2025-03-28
$1.02M
10-K · filed 2025-03-28
2023-09-30$277.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14
$673.00K
derived: sum of 2 quarters · filed 2024-11-14
$782.00K
10-Q · filed 2024-11-14
$782.00K
derived: sum of 4 quarters · filed 2024-11-14
2023-06-30$396.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14
$505.00K
10-Q · filed 2024-08-14
$505.00K
derived: sum of 3 quarters · filed 2024-08-14
$538.00K
derived: sum of 4 quarters · filed 2024-08-14
2023-03-31$109.00K
10-Q · filed 2024-05-09
$109.00K
derived: sum of 2 quarters · filed 2024-05-09
$142.00K
derived: sum of 3 quarters · filed 2024-05-09
$143.00K
derived: sum of 4 quarters · filed 2024-05-09
2022-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29
$33.00K
derived: sum of 2 quarters · filed 2024-03-29
$34.00K
derived: sum of 3 quarters · filed 2024-03-29
$49.00K
10-K · filed 2024-03-29
2022-09-30$33.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14
$34.00K
derived: sum of 2 quarters · filed 2023-11-14
$49.00K
10-Q · filed 2023-11-14
2022-06-30$1.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14
$16.00K
10-Q · filed 2023-08-14
2022-03-31$15.00K
10-Q · filed 2023-05-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
BICYCLE THERAPEUTICS PLC (BCYC)$0.112B-1.56
Equillium, Inc. (EQ)United States$0.109B-11.27
Quantum Cyber N.V. (QUCY)$0.113B
Immuneering Corp (IMRX)United States$0.113B-12.51
Biomea Fusion, Inc. (BMEA)United States$0.107B-3.30
Polaryx Therapeutics, Inc. (PLYX)United States$0.106B
ProMIS Neurosciences Inc. (PMN)$0.102B
OnKure Therapeutics, Inc. (OKUR)United States$0.119B-3.13
Coya Therapeutics, Inc. (COYA)United States$0.121B-6.35
CUMBERLAND PHARMACEUTICALS INC (CPIX)United States$0.121B-8.95